Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 tirzepatide vs placebo in adults with type 1 diabetes and overweight/obesity
jRCT2031250060Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- May 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
01
Overview
Phase 3, randomised, double-blind trial of tirzepatide in diabetes mellitus type 1 (T1D), obesity and Overweight (5 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change from baseline in HbA1c at Week 40. Started May 2025; status: active, not recruiting.
02
Drugs
03
Conditions
diabetes mellitus type 1 (T1D)obesityOverweight
Beyond the preview
Go deeper on jRCT2031250060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250060.